Bcr-Abl variants: biological and clinical aspects (Q34145565)

31 July 2017

1 reference

title

Bcr-Abl variants: biological and clinical aspects (English)

1 reference

31 July 2017

Anjali S Advani

1 reference

31 July 2017

Ann Marie Pendergast

series ordinal

1 reference

31 July 2017

publication date

1 August 2002

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

713-720

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myelogenous leukemia: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Therapy and prognostic factors in adult acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Options for therapy in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Lineage switch in Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The significance of cytogenetic findings of erythroid colonies derived from a Ph+ ALL patient: fundamental differences between Ph+ ALL and blastic phase CML

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Difference of cell lineage expression of haematopoietic progenitor cells in Philadelphia-positive acute lymphoblastic leukaemia and chronic myelogenous leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

2 BCR-ABL gene variants

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR/ABL rearrangement and leukemia phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Dominant negative MYC blocks transformation by ABL oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

A Cytoplasmic Inhibitor of the JNK Signal Transduction Pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Differential complementation of Bcr-Abl point mutants with c-Myc

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Abl tyrosine kinase in signal transduction and cell-cycle regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Mouse disabled (mDab1): a Src binding protein implicated in neuronal development

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Tyrosine phosphorylation of tub and its association with Src homology 2 domain-containing proteins implicate tub in intracellular signaling by insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Novel therapies for chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Genetic Approaches to Defining Signaling by the CML-associated Tyrosine Kinase BCR-ABL

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Signaling by ABL oncogenes through cyclin D1.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Sequence and Analysis of the Human ABL Gene, the BCR Gene, and Regions Involved in the Philadelphia Chromosomal Translocation

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Cytogenetic studies of haemopoietic colonies from patients with an initial diagnosis of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Definition of the accelerated phase of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Karyotypic findings as an independent prognostic marker in chronic myeloid leukaemia blast crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Inversion of chromosome 16 and bone marrow eosinophilia in a myelomonocytic transformation of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

1 reference

7 January 2021

p53 in chronic myelogenous leukemia in acute phase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The role of myc in transformation by BCR-ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Changes in oncogene expression implicated in evolution of chronic granulocytic leukemia from its chronic phase to acceleration

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

The cytogenetic scenario of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Transforming genes in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

BCR/ABL inhibition by an escort/phosphatase fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2801%2900197-7

7 January 2021

10.1016/S0145-2126(01)00197-7

Identifiers

DOI

1 reference

31 July 2017

1 reference